推荐产品
一般說明
designed to simplify the identification and characterization of SARS-CoV-2 inhibitors.
應用
The SARS-CoV-2 Inhibitors Screening Kit is a convenient tool, designed to simplify the identification and characterization of SARS-CoV-2 inhibitors.The crutial interaction between the SARS-CoV-2 and human cells accrues through the protein-protein interaction of human receptor ACE2 and viral protein Spike – S protein. The receptor binding domain (RBD) of S protein is the domain that specifically binds to ACE2. Our SARS-CoV-2 Inhibitors Screening Kit includes both human ACE protein and viral RBD of S protein. The kit is based on a colorimetric ELISA, where biotinylated ACE2 (ACE2-biotin) and Extravidin®-peroxidase are used to detect the ACE2:RBD interaction. One molecule of Extravidin® binds four molecules of biotin by a non-covalent interaction that is essentially irreversible. Binding visualization is achieved by using o-Phenylenediamine dihydrochloride (OPD), a peroxidase substrate with absorbance at 450 nm.
Inhibitors and neutralizing antibodies against RBD that interfere with the ACE2:RBD interaction will result in reduced colorimetric signal.
Inhibitors and neutralizing antibodies against RBD that interfere with the ACE2:RBD interaction will result in reduced colorimetric signal.
生化／生理作用
SARS-CoV-2 - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) belongs to Coronaviridae (CoVs) - a large family of viruses that usually cause mild to moderate upper-respiratory tract diseases.1 CoVs are single-stranded RNA viruses. They have a high mutation rate and are therefore highly diverse.1 Their hosts include human and non-human mammals, as well as birds.1
SARS-CoV-2 infects cells which express angiotensin converting enzyme 2 (ACE2).2 ACE2 binds to the viral envelope-associated spike (S) protein as a cellular receptor, following proteolytic cleavage of both S and ACE2 by serine proteases.3 S protein is believed to be the target of neutralizing antibodies because it is the main trans-membrane glycoprotein responsible for receptor-binding and virion entry.4
The S protein is a trimeric protein. During the binding to ACE2, S protein undergoes a substantial structural rearrangement to facilitate the fusion of the viral membrane with the host cell membrane.5 The receptor binding domain (RBD) of S protein is the domain that specifically binds to ACE2. RBD is the major target for neutralizing antibodies for coronaviruses6, and anti-RBD antibodies likely correlate with virus neutralization.7
SARS-CoV-2 infects cells which express angiotensin converting enzyme 2 (ACE2).2 ACE2 binds to the viral envelope-associated spike (S) protein as a cellular receptor, following proteolytic cleavage of both S and ACE2 by serine proteases.3 S protein is believed to be the target of neutralizing antibodies because it is the main trans-membrane glycoprotein responsible for receptor-binding and virion entry.4
The S protein is a trimeric protein. During the binding to ACE2, S protein undergoes a substantial structural rearrangement to facilitate the fusion of the viral membrane with the host cell membrane.5 The receptor binding domain (RBD) of S protein is the domain that specifically binds to ACE2. RBD is the major target for neutralizing antibodies for coronaviruses6, and anti-RBD antibodies likely correlate with virus neutralization.7
特點和優勢
Our SARS-CoV-2 Inhibitors Screening Kit will support your research, enabling to screen and discover inhibitors as potential drugs for COVID-19
Supportive calculator (Click here to download a calculator excel file)
法律資訊
ExtrAvidin is a registered trademark of Merck KGaA, Darmstadt, Germany
訊號詞
Danger
危險分類
Acute Tox. 4 Oral - Aquatic Chronic 2 - Carc. 2 - Eye Dam. 1 - Muta. 2 - Skin Sens. 1 - STOT SE 3
標靶器官
Respiratory system
儲存類別代碼
10 - Combustible liquids
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门